264 related articles for article (PubMed ID: 9290695)
1. Update on active specific immunotherapy with melanoma vaccines.
Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
[TBL] [Abstract][Full Text] [Related]
2. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
Ollila DW; Kelley MC; Gammon G; Morton DL
Semin Surg Oncol; 1998 Jun; 14(4):328-36. PubMed ID: 9588726
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response to anticancer immunotherapy using gene signatures.
Wang E; Bedognetti D; Marincola FM
J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
[No Abstract] [Full Text] [Related]
4. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
5. Melanoma vaccines.
Minev BR
Semin Oncol; 2002 Oct; 29(5):479-93. PubMed ID: 12407513
[TBL] [Abstract][Full Text] [Related]
6. An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.
Ralph SJ
Am J Clin Dermatol; 2007; 8(3):123-41. PubMed ID: 17492842
[TBL] [Abstract][Full Text] [Related]
7. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
8. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
9. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
11. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
12. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
[TBL] [Abstract][Full Text] [Related]
13. Tumor vaccines: a role in preventing recurrence in melanoma?
Sabel MS; Sondak VK
Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
[TBL] [Abstract][Full Text] [Related]
14. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine.
Horvath JC; Horak A; Sinkovics JG; Pritchard M; Pendleton S; Horvath E
Acta Microbiol Immunol Hung; 1999; 46(1):1-20. PubMed ID: 10331063
[TBL] [Abstract][Full Text] [Related]
15. Melanoma vaccines.
Perales MA; Wolchok JD
Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
17. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
[TBL] [Abstract][Full Text] [Related]
18. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
19. Novel immunologic approaches to the management of malignant melanoma.
Weber JS; Aparicio A
Curr Opin Oncol; 2001 Mar; 13(2):124-8. PubMed ID: 11224710
[TBL] [Abstract][Full Text] [Related]
20. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
